← Back to Screener
Dyne Therapeutics, Inc. Common Stock (DYN)
Price$17.04
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-30.12%
Price vs S&P 500 (4W)-3.23%
VGM Score63.80
Market Capitalization$2.82B
All Metrics
Book Value / Share (Quarterly)$5.24
P/TBV (Annual)2.69x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.80
Price vs S&P 500 (YTD)-21.04%
EPS (TTM)$-3.22
10-Day Avg Trading Volume1.52M
EPS Excl Extra (TTM)$-3.22
EPS (Annual)$-3.47
ROI (Annual)-39.80%
Cash / Share (Quarterly)$5.88
ROA (Last FY)-37.59%
EBITD / Share (TTM)$-3.30
ROE (5Y Avg)-92.38%
Cash Flow / Share (Annual)$-2.57
P/B Ratio3.26x
P/B Ratio (Quarterly)3.46x
Net Income / Employee (Annual)$-1,729,500
Net Interest Coverage (TTM)-173.82x
ROA (TTM)-46.77%
EPS Incl Extra (Annual)$-3.47
Current Ratio (Annual)22.25x
Quick Ratio (Quarterly)18.97x
3-Month Avg Trading Volume1.92M
52-Week Price Return21.80%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.48
52-Week High$25.00
EPS Excl Extra (Annual)$-3.47
CapEx CAGR (5Y)77.97%
26-Week Price Return-22.19%
Quick Ratio (Annual)21.94x
13-Week Price Return12.11%
Total Debt / Equity (Annual)0.15x
Current Ratio (Quarterly)19.92x
Enterprise Value$2.22B
Book Value / Share Growth (5Y)-4.93%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.73
3-Month Return Std Dev75.05%
Net Income / Employee (TTM)$-1,750,800
ROE (Last FY)-45.90%
EPS Basic Excl Extra (Annual)$-3.47
Total Debt / Equity (Quarterly)0.18x
EPS Incl Extra (TTM)$-3.22
ROI (TTM)-50.15%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.54
Price vs S&P 500 (52W)-2.56%
Year-to-Date Return-12.88%
5-Day Price Return-8.53%
EPS Normalized (Annual)$-3.47
ROA (5Y Avg)-63.28%
Month-to-Date Return-11.85%
Cash Flow / Share (TTM)$-3.59
EBITD / Share (Annual)$-3.63
LT Debt / Equity (Annual)0.15x
ROI (5Y Avg)-91.16%
LT Debt / Equity (Quarterly)0.17x
EPS Basic Excl Extra (TTM)$-3.22
P/TBV (Quarterly)4.46x
P/B Ratio (Annual)3.26x
Book Value / Share (Annual)$5.89
Price vs S&P 500 (13W)3.85%
Beta1.16x
Revenue / Share (TTM)$0.00
ROE (TTM)-58.28%
52-Week Low$8.06
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.73est. -0.78
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DYNDyne Therapeutics, Inc. Common Stock | — | — | B | $17.04 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Dyne Therapeutics is a clinical-stage biopharmaceutical company developing treatments for genetically driven neuromuscular diseases. Its proprietary FORCE platform addresses a critical delivery challenge to muscle tissue and the central nervous system that limits existing therapies. The company has multiple programs in clinical development targeting distinct neuromuscular indications.